Deregulation of the tyrosine kinase signalling is often associated with tumour progression and drug resistance, but its underlying mechanisms are only partly understood. In this study, we investigated the effects of the receptor tyrosine kinase AXL on the stability of the MDMX-MDM2 heterocomplex and the activity of p53 in melanoma cells. Our data demonstrated that AXL overexpression or activation through growth arrest-specific 6 (Gas6) ligand stimulation increases MDMX and MDM2 protein levels and decreases p53 activity. Upon activation, AXL stabilizes MDMX through a post-translational modification that involves phosphorylation of MDMX on the phosphosite Ser314, leading to increased affinity between MDMX and MDM2 and favouring MDMX nuclear translocation. Ser314 phosphorylation can also protect MDMX from MDM2-mediated degradation, leading to stabilization of the MDMX-MDM2 complex. We identified CDK4/6 and p38 MAPK as the two kinases mediating AXL-induced modulation of the MDMX-MDM2 complex, and demonstrated that suppression of AXL, either through siRNA silencing or pharmacological inhibition, increases expression levels of p53 target genes P21, MDM2, and PUMA, improves p53 pathway response to chemotherapy, and sensitizes cells to both Cisplatin and Vemurafenib. Our findings offer an insight into a novel signalling axis linking AXL to p53 and provide a potentially druggable pathway to restore p53 function in melanoma.
Introduction
One of the hallmarks of malignant tumour development is loss of p53, either via mutation or functional inactivation. Cancers that retain wild-type (wt) p53 find alternative ways to suppress its function by aberrantly deregulating either upstream modulators or downstream effectors. The two major essential negative regulators of p53 are MDM2 and MDMX, two homologue proteins that modulate p53 transcriptional activity and protein turnover (Wade et al., 2013) . Despite sharing a high degree of sequence similarity, MDM2 and MDMX have nonoverlapping functions (Shadfan et al., 2012) , since knockout of either of them can cause p53-dependent embryonic lethality (Pant et al., 2011) . Both proteins contain a RING domain, whilst only MDM2 contains both a nuclear localization signal (NLS) domain and a nuclear export signal (NES) domain. The RING finger domain of MDM2 provides E3 ligase activity, promoting its nuclear export and proteosomal degradation. MDMX also contains a RING domain, but shows very little E3 ligase activity and cannot be shuttled into the nucleus unless bound to MDM2 (Bond et al., 2005; Itahana et al., 2007; Huang et al., 2011; Pant et al., 2011) . However, it can enhance MDM2 ligase activity and also binds to the transactivation domain of p53 and suppresses its transcriptional activity, both independently and cooperatively with MDM2. Together, p53, MDMX, and MDM2 form a regulatory node that is highly dynamic and contains positive and negative feedback loops (Wade et al., 2013) . MDM2 can target p53 for degradation, but is also a p53 transcriptional target gene itself, creating a negative loop controlling p53 turnover. MDMX interaction with MDM2 increases MDM2 protein stability and E3 ligase activity, but MDMX can also be targeted for degradation by MDM2, especially when, under stress conditions, MDM2 activity is diverted from p53 to MDMX, generating another negative feedback loop that buffers MDM2 activity. This complex and dynamic regulatory core ensures a fine-tuned modulation of p53 under non-stress conditions and its quick and effective activation under conditions of stress, i.e. in response to DNA damage, hypoxia, or oncogenic stress (Wade et al., 2013) .
Cutaneous melanoma is one of the cancers with the lowest mutation rate of p53 (<10%) (Chin, 2003; Chin et al., 2006; Hodis et al., 2012) , but the suppression of its transcriptional activity is crucial for melanoma development and progression (Bardeesy et al., 2001; Dovey et al., 2009; Goel et al., 2009; Gao et al., 2013) . However, the underlying mechanisms of p53 inactivation are only partly understood (Curtin et al., 2005) . In wt p53-expressing cutaneous melanoma, the frequency of MDM2 and MDMX protein alterations is 46% and 85%, respectively (Wade et al., 2013) , second only to breast cancer, pointing at a major oncogenic role of MDM proteins in melanoma. Consistent with this, overexpression of MDMX has been shown to promote tumorigenesis in a mouse model harbouring oncogene NRAS, and the disruption of the MDMX-p53 interaction resulted in enhanced efficacy of Cisplatin and Vemurafenib treatment (Gembarska et al., 2012) . However, Nutlin3 treatment in wt p53-expressing melanoma cells only caused modest reactivation of p53 (De Lange et al., 2012; Ji et al., 2012) , suggesting that targeting only MDM2-p53 interaction may not be sufficient to effectively restore p53 pathway. Genetic studies performed (Huang et al., 2011; Pant et al., 2011) have shown that MDMX and MDM2 exert their control on p53 more efficiently when working together as a complex, rather than singularly. Taken together, these observations suggest that targeting the stability of the MDMX-MDM2 complex could potentially provide a more effective strategy to rescue p53 than therapies targeted only MDMX or MDM2.
As the essential upstream modulator of p53, the MDMX-MDM2 complex integrates multiple intra-and extracellular signalling pathways regulating p53 response to perturbations of cellular homoeostasis (Chen, 2012; Li and Kurokawa, 2015) . Among the main mediators of extracellular signalling input are receptor tyrosine kinases (RTKs), high affinity receptors for many ligands, including growth factors, hormones, and cytokines (Robinson et al., 2000) . In normal cells, RTKs are responsible for transducing extracellular signals and contribute to the maintenance of cellular homoeostasis by controlling diverse biological processes like growth, differentiation, and metabolism (Paul and Mukhopadhyay, 2004; Linger et al., 2008) . In transformed cells, constitutive oncogenic activation of RTK signalling can enable cells to evade tightly regulated cellular processes, leading to cancer progression and therapy resistance. Given that p53 functional deactivation is required for tumorigenesis in wt p53-harbouring tumours, it is plausible that oncogenic kinase signalling could target the MDMX-MDM2 complex, disrupting the dynamics of the MDMX-MDM2-p53 core and suppressing p53 ability to preserve cellular homoeostasis. We hypothesized that this model is conserved across wt p53-expressing tumours, among which we selected melanoma, for its low frequency of p53 mutation (Chin, 2003; Chin et al., 2006; Hodis et al., 2012) , and high frequency of MDM protein alterations (Wade et al., 2013) . By performing a genomic screening of a RTK library, we identified 11 RTKs whose expression was associated with inhibition of DNA damage-induced p53 activation via modulation of the MDMX-MDM2 heterocomplex stability. Among these 11 RTKs, we chose to focus on the transmembrane RTK AXL, since AXL oncogenic signal can promote proliferation, migration, and invasion (Holland et al., 2005; Sensi et al., 2011; Paccez et al., 2014; Zagó rska et al., 2014) and has been associated with a multidrug resistance phenotype in melanoma (Konieczkowski et al., 2014; Müller et al., 2014) .
AXL belongs to the Tyro-Axl-Mer (TAM) family of RTKs, which also includes Tyro3 and Mer (Paccez et al., 2014; scaltriti et al., 2016) . Overexpression or activation of AXL has been reported in many tumours, including kidney (Yu et al., 2015 , Zhou et al., 2016 , lung (Shinh et al., 2005) , triple negative breast (Meric et al., 2002) , and prostate cancer (Paccez et al., 2013) . Importantly, AXL suppression has been recently shown to improve chemosensitivity of neuroblastoma cells , suggesting a potential link between the pleiotropic functions of AXL and the suppression of p53 functions. In melanoma, a high-AXL/low-MITF phenotype has been associated with resistance to multiple targeted drugs (Konieczkowski et al., 2014; Müller et al., 2014) . Another study used a whole-genome expression analysis to dissect the mechanisms of acquired resistance to BRAF inhibitor and identified AXL and epidermal growth factor receptor (EGFR) as two receptors activated upon BRAF inhibitor resistance. However, only EGFR suppression was more effective in sensitizing cells to the inhibitor (Ji et al., 2015) .
In this study, we investigated the effects of AXL activation on the MDMX-MDM2 complex stability and p53 activity in melanoma cells. Our findings demonstrated that AXL overexpression leads to the stabilization of MDMX through a process that is partly mediated by the phosphosite Ser314 on MDMX. We identified CDK4/6 and p38 MAPK as the two kinases mediating the phosphorylation at Ser314 and demonstrated that suppression of AXL, either through silencing or pharmacological inhibition, can improve p53 response to chemotherapy.
Results

AXL expression stabilizes MDMX and MDM2 and suppresses p53 transcriptional activity
AXL was identified by a mammalian two-hybrid screening assay performed to search for oncogenic pathways that could affect p53 activity through regulating the MDMX-MDM2 complex (data not shown). Of the 75 kinases screened, 11 candidate kinases, including AXL, were identified and tested for their effect on irradiation-induced p53 activation using β-galactosidase staining as a readout of irradiation-induced senescence. We verified this finding by co-expressing AXL with MDMX and MDM2 in 293T cells. Western blot analysis confirmed that AXL expression leads to increased levels of MDMX and MDM2 ( Figure 1A ) and decreased protein levels of p53 ( Figure 1B) . To test whether AXL could affect the formation of the heterodimer, we next co-expressed AXL with MDMX and FLAG-tagged MDM2, and performed an anti-FLAG immunoprecipitation (FLAG-IP) using FLAG-conjugated beads. Indeed, FLAG-IP of MDM2 showed that the MDMX-MDM2 complex was enriched in the presence of AXL ( Figure 1C) .
Since MDMX is normally localized in the cytoplasm and MDM2 in the nucleus, we hypothesized that MDMX, rather than MDM2, was the most probable target of an RTK-mediated signalling pathway. Therefore, we focused on MDMX and assessed its protein levels upon AXL stimulation in A375 melanoma cells. This cell line was selected among a panel of melanoma cell lines (Supplementary Figure S1A) because it expresses constitutively high levels of AXL and wt p53. Upon stimulation with growth arrest-specific 6 (Gas6) ligand, MDMX levels were increased ( Figure 1D ), confirming that this mechanism is conserved also in melanoma cells. To test whether the protein stability of MDMX was increased by AXL activation, we assessed MDMX half-life in A375 cells after stimulation with Gas6 and observed that MDMX half-life was indeed significantly extended by AXL stimulation ( Figure 1E ). Similar results were obtained through both overexpression and silencing of AXL in A375 cells (Supplementary 293T cells were transfected with control, MDMX, MDM2, and AXL expression plasmids for 36 h, and cell lysates were analysed by western blot using the indicated antibodies. (C) 293T cells were transfected with a combination of expression vectors for FLAG-tagged MDMX and MDM2, with or without AXL, and harvested 36 h after using FLAG-conjugated beads. Western blot analysis was performed using the indicated antibodies. (D) A375 cells were serum-starved overnight and then treated with 0, 50, or 100 nM of Gas6 for 6 h. Western blot analysis was carried out with the indicated antibodies. (E) A375 cells were serum-starved overnight and treated with 100 nM of Gas6 for 24 h. Cells were then treated with 100 μg/ml of cycloheximide for the indicated time points. (i) Anti-MDMX and anti-GAPDH antibodies were used for western blot analysis. (ii) Relative amount of MDMX densitometry was calculated using ImageJ. (F) Two different strands of siRNAs against AXL (siAXL-1 and siAXL-2) and same amount of control siRNA (siCtrl) were transfected into A375 cells. (i) Cell lysates were harvested for western blot analysis 48 h after transfection using the indicated antibodies. (ii) Total RNA extracted from each sample was used for qPCR analysis of MDMX and ACTB mRNA expression. ACTB mRNA was used as an internal control. (G) Luciferase reporter pg13, Renilla, and different amounts of AXL expression plasmids were co-transfected into 293T cells, and the p53 activity was analysed by a luciferase assay as described in 'Materials and methods' section. E.V., empty vector. Figure S1B ). In line with this finding, MDMX mRNA levels were unchanged upon AXL knockdown, whereas its protein expression levels were decreased ( Figure 1F) .
To determine the effects of AXL on p53 activity, we utilized a luciferase reporter containing 13 copies of the p53-binding consensus sequence (pg13) and expressed it in 293T cells, along with increasing concentrations of an AXL expression plasmid. The luciferase reporter assay showed that AXL could significantly suppress p53 transcriptional activity in a dose-dependent way ( Figure 1G ). Furthermore, when AXL was co-expressed with MDMX-MDM2, there was a further reduction of luciferase activity ( Figure 1H ), indicating that AXL contributes to p53 suppression both alone and in the presence of the MDMX-MDM2 complex. As summarized in Figure 1I , these results suggest that AXL can increase MDMX and MDM2 protein stability, either directly or indirectly, leading to suppression of p53 levels and activity.
AXL induces MDMX Ser314 phosphorylation through the kinases CDK4/6 and p38
In order to dissect the mechanism behind the stabilization of the MDMX-MDM2 complex, we analysed the phosphorylation signature of MDMX and MDM2 in the heterocomplex form, in the presence or absence of AXL. 293T cells were transfected with plasmids expressing FLAG-tagged MDMX and MDM2, either alone or in the presence of AXL. The MDMX-MDM2 complex was enriched by FLAG-IP and then analysed by LC-MS/MS. According to the list of identified phosphosites (data available upon request), no change was observed in MDM2 phosphorylation status upon AXL overexpression, whilst there was a clear increase of MDMX phosphorylation at Ser314 (Figure 2A -i), a novel phosphosite located in the zinc-finger domain of MDMX ( Figure 2A -ii). The same phosphosite was identified in our lab upon expression of another RTK (Gerarduzzi et al., 2016) , suggesting that Ser314 may represent a converging point of multiple RTK-mediated signalling pathways. Scanning of the phosphosite with the kinase prediction software GPS (Xue et al., 2008) for potential candidates responsible for phosphorylating Ser314, we identified CDK4/6 and p38 as the two kinases mediating AXL signal (Figure 2A-iii) .
To verify the results of the LC-MS/MS analysis, a MDMX (S314A) mutant was expressed in 293T cells in various combinations with AXL and MDM2 ( Figure 2B ). In the presence of AXL, MDMX levels were increased, as expected, when wt MDMX plasmid was expressed, but they did not appear to be decreased when MDMX(S314A) mutant was expressed. MDM2, on the contrary, was strongly stabilized by AXL expression in the presence of wt MDMX, but this stabilization was partly lost when MDMX (S314A) mutant was expressed instead. Similar co-expression experiments were performed with p38 and CDK4 to validate the prediction of the GPS software. According to western blot analysis, p38 was able to stabilize MDMX and MDM2, both alone and in combination, and this stabilization was partly lost when p38 and MDM2 were co-expressed with MDMX(S314A) mutant instead of wt MDMX ( Figure 2C) . Similarly, CDK4 expression resulted in increased levels of MDMX and MDM2, both alone and in combination ( Figure 2D-i) . When MDMX(S314A) mutant was expressed instead of wt MDMX, the stabilization of MDM2, but not that of MDMX, was partly lost, as in the case of AXL ( Figure 2D-ii) . Using an anti-phosphoserine antibody, we were able to detect a strong band at 80 kDa when wt MDMX was coexpressed with CDK4 and MDM2, whereas the band was partly lost when MDMX(S314A) mutant was expressed ( Figure 2D -ii). Furthermore, an in vitro kinase assay demonstrated that both CDK4 and p38 could directly phosphorylate wt MDMX, but not the S314A mutant of MDMX ( Figure 2E ). The residual band observed in the MDMX(S314A) lane suggests that Ser314 is the primary site for CDK4 and p38, but there might be other, yet uncharacterized CDK4 and p38 sites on MDMX.
To validate the role of CDK4/6 and p38 as mediators of AXL signalling on the MDMX-MDM2 complex, we expressed AXL in 293T cells and then treated them with either Palbociclib (Pfizer) or BIRB 796 (Doramapimod, Boehringer Ingelheim Pharmaceutical), two inhibitors of CDK4/6 and p38, respectively. As shown in Figure 2F -i, AXL expression led to an increase in MDMX and MDM2 levels, as expected, but it also resulted in an increase in phosphorylation of the retinoblastoma (Rb) protein, a marker of Cyclin D1-CDK4/6 complex activation and Rb suppression. By hyperphosphorylating Rb, activated CDK4/6 renders Rb unable to inhibit the E2F transcription factor and therefore unable to restrict progression from the G1 phase to the S phase of cell cycle (Giacinti and Giordano, 2006) . Our results show that Rb suppression by CDK4/6 can be induced by AXL. More importantly, pharmacological inhibition of CDK4/6 was able to abrogate AXL effect on MDMX and MDM2, confirming the role of CDK4/6 as downstream effector of AXL signalling. Similarly, AXL expression resulted in MDMX and MDM2 stabilization and activation (through phosphorylation) of p38 ( Figure 2F -ii), but 30 nM of the p38 inhibitor BIRB were sufficient to abrogate AXL-induced p38 phosphorylation as well as MDMX and MDM2 was carried out using immunopurified FLAG-tagged MDMX or MDMX(S314A) proteins incubated with cell lysates expressing constitutively active CDK4 or p38, or kinase-dead (K.D.) CDK4 or p38, in the presence or absence of adenosine triphosphate (ATP). The products were analysed by western blot using anti-phosphoserine antibody (upper panel) induction, confirming the role of p38 as mediator of AXL signalling, along with CDK4/6. Although both kinases seem to be involved in AXL signalling, we decided to focus only on the AXL-CDK4/6-MDMX/MDM2-p53 axis but not on p38, because p38 is known to be able to directly phosphorylate and activate p53 upon DNA damage stress signal (Wu, 2004) , leading to p53-mediated apoptosis, and this mechanism could counteract the pathway we are studying. We speculate that both mechanisms are likely to be in place, but one might become predominant over the other, depending on the type and/or intensity of the stress signal.
In order to validate these results in melanoma cells, we used a low AXL-expressing melanoma cell line, M14, and exogenously expressed AXL and CDK4, either alone or in combination, followed by treatment with CDK4/6 inhibitor Palbociclib ( Figure 2G) . AXL-induced stabilization of MDMX, which was further stabilized by CDK4 co-expression, was partly suppressed by CDK4/6 inhibitor. In this cell line, CDK4 alone was not able to stabilize MDM2, possibly since these cells already express relatively high levels of CDK4/6. However, treatment with CDK4/6 inhibitor strongly suppressed MDM2, confirming the role of this cyclin kinase on the MDMX-MDM2 complex.
Since AXL is known to regulate the pro-survival PI3K/Akt signalling pathway (Paccez et al., 2014) , and previous studies have shown that Akt can stabilize MDMX (Lopez-Pajares et al., 2008), we wanted to test whether the PI3K/Akt pathway was also mediating AXL signalling on MDMX, alongside CDK4/6 and p38. To this end, 293T cells were transfected with control plasmid or AXL and then treated with either the multi-tyrosine inhibitor Foretinib (GSK1363089, GlaxoSmithKline), the AXL-specific inhibitor R428 (BGB324, Rigel Pharmaceuticals, BergenBio), or the PI3K inhibitor LY294002. Western blot analysis showed that only Foretinib was able to suppress AXL effect on both MDMX and MDM2. R428 abrogated the effect of AXL on MDM2, whereas LY294002 did not affect MDMX or MDM2 expression, despite effectively suppressing Akt phosphorylation, indicating that the PI3K/Akt pathway does not mediate MDMX stabilization upon AXL activation ( Figure 2H) .
Taken together, these results indicate that AXL induces MDMX phosphorylation, leading to MDMX and MDM2 stabilization, and that this effect is at least partly mediated by the kinases CDK4/6 and p38 ( Figure 2I ).
AXL increases MDMX-MDM2 affinity and protects MDMX from MDM2-mediated degradation
With our data indicating that AXL affects MDMX protein but not transcript levels, we wanted to further dissect the mechanisms that lead to the stabilization of the MDMX-MDM2 complex. Give that the Ser314 phosphosite is located in the zinc-finger domain of MDMX (Figure 2A-ii) , which is required for MDMX and MDM2 binding, and residues in the C-terminal region of both MDMX and MDM2 have been shown by crystal structure studies to play a key role in dimmer formation (Linke et al., 2008) , we speculated that AXL-mediated phosphorylation of MDMX leads to the stabilization of the heterocomplex because it seems to increase the binding affinity between the two proteins. We utilized a mammalian two-hybrid system to test whether the presence of AXL could increase the binding between MDMX and MDM2. A luciferase reporter assay was used, in which the reporter plasmid, pGal4-Luc, was co-expressed with a Gal4-binding domain fused to MDM2, and a VP16-activation domain was fused to MDMX. When AXL was expressed, we observed a significant and dose-dependent increase in the luciferase signal, compared with the two-hybrid construct alone, which was abrogated by either Foretinib or the CDK4/6 inhibitor Palbociclib, confirming the specificity of AXL signal and the role of CDK4/6 in this mechanism ( Figure 3A-i, ii) . Moreover, co-expression of AXL with MDMX(C462A), a mutant MDMX carrying a mutation in its RING domain that disrupts MDMX-MDM2 binding, failed to fully stabilize MDM2 and suppress p53 levels, as compared with co-expression with wt MDMX ( Figure 3B) . Overall, these data not only support the hypothesis that AXL stabilizes the MDMX-MDM2 complex at least partly by increasing their binding affinity, but also demonstrate that the stabilization of MDM2 by AXL is mediated by MDMX.
Furthermore, since MDMX can be targeted by MDM2 for degradation, we also hypothesized that AXL phosphorylation of MDMX at Ser314 protects it from MDM2-mediated degradation, leading to increased MDMX half-life and, overall, increased stability of the whole complex. We first used siRNA against MDM2 to rescue the destabilization of MDMX caused by AXL knockdown. For this experiment, we used the p53-mutant melanoma cell line SK-MEL-28, since knockdown of MDM2 can very potently activate p53, leading to unwanted cell growth arrest in wt p53-expressing cells. Indeed, MDM2 knockdown was able to rescue MDMX suppression upon AXL knockdown ( Figure 3C) . Moreover, when knockdown of AXL was followed by proteasome inhibitor treatment, MDMX levels were very effectively rescued, suggesting that AXL expression can protect MDMX from proteasome degradation ( Figure 3D ).
AXL phosphorylation of MDMX on Ser134 favours MDMX nuclear transport
Since it harbours both a NLS and a NES, MDM2 can be found both in the nucleus and in the cytoplasm, whilst in the absence of stress, MDMX is predominantly cytoplasmic and depends on MDM2 binding to translocate into the nucleus, where the MDMX-MDM2 complex can interact with p53. Since it has been shown that phosphorylation of MDMX can affect its cellular distribution (Pereg et al., 2005; Chen, 2012) , and having demonstrated that AXL expression increases MDMX and MDM2 binding affinity, we hypothesized that AXL-mediated phosphorylation of MDMX on Ser314 favours the nuclear translocation of MDMX, which is predominantly MDM2-dependent. This hypothesis was tested through immunostaining of 293T cells (for exogenous expression, Figure 4A -i) and melanoma cell lines (SK-MEL-30, for endogenous expression, Figure 4B -i). Although MDMX was distributed both in the nucleus and in the cytoplasm, upon AXL expression, MDMX nuclear localization increased, whereas coexpression of AXL with MDMX(S314A) did not affect its cellular distribution ( Figure 4A and B) . AXL co-expression with wt MDMX was also associated with increased nuclear export of p53 (Supplementary Figure S2) , whilst this effect was partly lost when MDMX(S314A) was expressed.
AXL and CDK4 inhibition increases the expression of p53 target genes
Having dissected the mechanisms behind AXL activation and the stabilization of the MDMX-MDM2 complex, we next wanted to link these observations to p53 activity in melanoma cells. To this end, the inhibitors R428, Foretinib, Palbociclib, and BIRB were tested in A375 cells for their effects on p53 target genes. With different degrees of efficacy (Supplementary Figure S3-1) , they all showed significant effects on the expression of p21, MDM2, and PUMA, offering potential strategies for p53 restoration in these cells.
In order to assess the effect of AXL expression on cell susceptibility to DNA damage stress and the relevance of the described axis on p53-related therapies, we silenced AXL by siRNA in A375 cells, treated them with the chemodrug Cisplatin, and assessed the response of p53 target genes. Western blot analysis showed that upon Cisplatin treatment, MDM2 protein levels were increased, assumingly as a result of p53 activation, and MDMX levels decreased due to increased MDM2-mediated degradation ( Figure 5A ). These effects on MDMX and MDM2 were further enhanced by AXL silencing ( Figure 5A ). In line with this observation, transcript levels of p53 target genes p21, MDM2, and PUMA displayed a significantly increased response to Cisplatin when AXL was knockdown, indicating that the MDMX-MDM2-mediated suppression of p53 was at least partly relieved upon AXL silencing (Supplementary Figure S3-2 ). An even stronger upregulation of p53 target genes was observed through pharmacological inhibition of AXL with two different inhibitors, R428 and Foretinib ( Figure 5B) , not only confirming the relevance of the AXL-CDK4/6-MDMX-MDM2 axis in p53 control, but also offering potentially novel therapeutic windows. To confirm the role of CDK4/6 in this axis, we performed a similar set of experiments, where A375 cells were treated with Cisplatin after suppression of CDK4/6 either through siRNA silencing ( Figure 5C ) or pharmacological inhibition ( Figure 5D ). As previously observed with AXL, CDK4/6 suppression was also very effective in restoring p53 function.
AXL suppression sensitizes cells to Cisplatin and Vemurafenib
To investigate whether AXL inhibition could improve the efficacy of Cisplatin, control and AXL-depleted cells were treated with increasing doses of Cisplatin, and cell viability was determined by AlamarBlue. The data showed that knockdown of AXL slightly increased the sensitivity of A375 cells to Cisplatin ( Figure 6A ), reducing the estimated IC50 compared with controls (95% confidence interval: between 9.5 and 13 μM in controls sets and between 6.6 and 7.8 μM in siAXL sets). Furthermore, the effect of Cisplatin on colony formation of AXL-depleted A375 was enhanced, compared with control cells, indicating that the anti-proliferative activity of the chemodrug was increased upon AXL suppression ( Figure 6B) .
Since it has been recently shown that concurrent p53 reactivation and BRAF V600E inhibition can achieve additive effect in vitro and in vivo (Sharpless and Chin, 2003; Box et al., 2014) , we tested the effect of R428 and Foretinib in combination with the BRAF V600E inhibitor Vemurafenib. In order to verify the p53-dependance of the observed effect, we developed a line of A375 cells with stable knockdown of p53 (Supplementary Figure S4-1) , and used this paired cell model to characterize the effects of the drug combinations in p53 wild-type versus p53 knockdown cells. Subacute doses of Vemurafenib induced a senescence phenotype, characterized by increased senescence-associated β-galactosidase activity ( Figure 6C ), changes in cell shape, and formation of promyelocytic leukaemia (PML) nuclear bodies (Supplementary Figure S4-2) . These senescence features were induced at a lower dose of Vemurafenib, when the drug was administrated in combination with R428 or Foretinib, indicating a possible sensitizing effect of AXL inhibitor to the BRAF V600E inhibitor treatment. Importantly, the sensitizing effect was lost, when the co-treatments were tested on p53 knockdown A375 cells ( Figure 6C, right panel) . In a colony formation assay, R428 and Foretinib were also able to further reduce cell proliferation in response to Vemurafenib treatment ( Figure 6D -i, ii) in both cell lines, but more effectively in p53 wild-type cells, suggesting partial p53-dependence of this mechanism. Collectively, these results suggest that AXL-induced modulation of the MDMX-MDM2 heterocomplex stability can suppress p53 activity, which in turn desensitizes cells to Cisplatin or Vemurafenib treatment. Hence, a combination therapy based on pharmacological inhibition of AXL (or potentially its downstream mediator CDK4/6) could improve cell sensitivity to chemotherapy or targeted therapy. 
Discussion
At present, the prevailing hypothesis explaining the low frequency of p53 mutation in melanoma is that inactivation of the CDKN2A locus, encoding the tumour suppressors p16 INK4A (which impacts on the retinoblastoma protein, Rb, pathway) and p14 ARF , makes mutation of p53 unnecessary (Sharpless and Chin, 2003) . In the presence of oncogenic activation, p14 ARF acts to directly inhibit the E3 ligase activity of MDM2, hence relieving p53 suppression, whereas in the presence of p14 ARF deletions, p53 is kept in check by the MDMX-MDM2 complex (Lu et al., 2013) . In light of this, p53 suppression in melanoma is likely to be controlled by signalling pathways that impact on the MDMX-MDM2 complex. Unravelling these pathways would prompt a re-examination of conventional chemotherapies, which have proven generally ineffective as standalone agents in melanoma treatment. For example, Dacarbazine, a powerful alkylating agent that induces p53-dependent death of tumour cells, has no ability to extend life in metastatic melanoma patients (Lu et al., 2013) . However, restoration of the p53 tumour suppression function through targeted inhibitors could be combined with conventional chemotherapeutics, like Dacarbazine or Cisplatin, to effectively target p53 pathway, or with other targeted therapies, such as the BRAF inhibitor Vemurafenib, to target two independent pathways, as it has been recently suggested (Lu et al., 2013) , and shown (Krayem et al., 2016) .
In this study, we provide evidence of a new signalling pathway controlling p53 in melanoma and we propose harnessing its antitumor potential through combination therapies. We show that p53 can be inhibited by the tyrosine kinase AXL, through a novel axis mediated by the kinases CDK4/6 and p38 and impinging on the MDMX-MDM2 complex. Although the oncogenic role of MDM proteins in melanoma has already been stressed by previous studies (De Lange et al., 2012; Gembarska et al., 2012; Ji et al., 2012) , the proposed therapeutic approaches were aimed at disrupting the interaction between p53 and either MDMX or MDM2. However, MDMX and MDM2 exert their control on p53 more efficiently when working as a complex, rather than singularly, so targeting the signalling pathway we describe here, which controls the stability of the MDMX-MDM2 complex, would potentially provide a more effective approach. A key aspect of our proposed therapeutic strategy is the sequential treatment; as it has been suggested before (Lee et al., 2012) , timestaggered inhibition of a specific receptor, but not simultaneous co-administration, can sensitize cells to genotoxic drugs by rewiring oncogenic signalling pathways. Similarly, our data demonstrated that pretreatment of melanoma cells with the targeted inhibitors Foretinib, R428, or Palbociclib can sensitize cells to Cisplain, enhancing the responsiveness of p53 target genes to the chemodrug. (1 μM), or Foretinib (1 μM) for 8 h, and then treated with Cisplatin for 3 h before being harvested. Total RNA was extracted and subjected to qPCR analysis with the indicated primers. (D) A375 cells were treated with DMSO or Palbociclib (30 nM) for 0, 4, or 24 h, followed by treatment with Cisplatin for 3 h. Total RNA was extracted and subjected to qPCR analysis with the indicated primers. Gene expression was normalized to ACTB. Bars indicate SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
We also tested the efficacy of R428 and Foretinib in combination with Vemurafenib and observed an increase in senescence markers upon co-treatment, stressing the relevance of p53 restoration not only in the context of chemotherapy but also in combination with targeted therapies. However, AXL signalling controls many cellular pathways (Shinh et al., 2005; Yu et al., 2015; Scaltriti et al., 2016; Zhou et al., 2016) , of which some do not directly involve p53, so the additive effects observed in our study are only partly dependent on the signalling axis we describe here. Therefore, further studies will be needed to fully explore the therapeutic potential of AXL inhibition in the context of melanoma therapy.
Materials and methods
Cell lines and reagents
293T, A375, SK-MEL-28, and M14 cell lines (ATCC) were maintained in Dulbecco's Modified Eagle's Medium (VWR). SK-MEL-30 was maintained in RPMI 1640 (VWR). All media were supplemented with 10% foetal bovine serum (HyClone), 100 IU Penicillin and 100 μg/ml Streptomycin (Corning). Recombinant human Gas6 protein was purchased from R&D Systems and prepared in sterile water; R428, Foretinib, Palbociclib, BIRB 796, and Cisplatin were purchased from Selleck Chemicals. Stock solution of Cisplatin was prepared in dimethylformamide, whilst the others were prepared in dimethyl sulfoxide (DMSO). All reagent stocks were stored in −20°C.
Plasmids transfection and siRNA
MDM2 and MDMX expression plasmids have been described previously (Gu et al., 2002) . CDK4, p38, and AXL plasmids were purchased from Addgene. pCDNA3-MDMX S314A mutant was generated by a two-step site-directed polymerase chain reaction (PCR) mutagenesis utilizing the following primers: 5′-TGTCGCTCCTGTC AACCTGTCGTT and 3′-CTCCTGTCAATGGTTCTTCG. Plasmid transfections were performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. All siRNAs were purchased from Sigma. Lipofectamine RNAiMax (Invitrogen) was used to transfect siRNA into cells.
shRNA-mediated gene suppression
To generate stable p53 knockdown cells, pLKO.1-shp53 with packaging plasmids PSPAX2 and PMD2-G (Addgene) were cotransfected into 293T cells, pLKO.1-scramble shRNA was used as control. All of these plasmids were purchased from Addgene. Supernatant containing lentiviral particles was collected at 48 and 72 h separately and used to infect A375 cells, followed by a selection using 2 μg/ml puromycin.
Western blot and immunoprecipitation
Cells were harvested and lysed in RIPA buffer with freshly added protease inhibitor and phosphatase inhibitor. Western blot was performed as described elsewhere (Gu et al., 2002) . transfected with scrambled siRNA (siCtrl) or siRNA targeted against AXL (siAXL). After 24 h, cells were split into 96-well plate for cell viability assay using AlamarBlue (A) or 6-well plate for colony formation assay (B). Cisplatin was used at increasing doses (50 nM, 100 nM, 500 nM, 1 μM, 2.5 μM, 5 μM, 7.5 μM, and 10 μM) for the cell viability assay and at the indicated doses for the colony formation assay. (C) p53 wildtype (A375-shCtrl) and p53 knockdown (A375-shp53) cells were seeded in 6-well plates and treated with Vemurafenib alone or combined with R428 or Foretinib at the indicated concentrations. SA-β-Gal staining was performed 10 days after treatment, and crystal violet staining was performed 8 days after treatment. Scale bar, 100 μm. (D) The intensity of crystal violet staining was measured by absorbance (i), and the relative difference of crystal violet staining between DMSO-treated and Foretinib-or R428-treated cells was calculated (ii, iii).
The following primary antibodies were used in this study: AXL (AF154-SP, R&D systems), phospho-AXL (#5724, Cell Signaling Technology), MDMX (#04-1555, Millipore), MDM2 (sc-965, Santa Cruz Biotechnology), p53 (sc-126, Santa Cruz Biotechnology), β-actin (sc-47778, Santa Cruz Biotechnology), GAPDH (#5174, Cell Signaling Technology), Flag (#4042, sigma), phosphoserine (ab9332, Abcam), CDK4/6 (#12790, Cell Signaling Technology), phospho-Rb (#8516, Cell Signaling Technology), and phosphop38 (#4511, Cell Signaling Technology). For immunoprecipitation, cell lysates were incubated with FLAG-M2 magnetic beads (Sigma) for 4 h before western blot analysis.
Dual-luciferase reporter assay
293T cells were co-transfected with pG13-luc, Renilla luciferase vector (Addgene), and different combinations of vectors as indicated. At 36 h post-transfection, cells were analysed using the Dual-Luciferase Assay (Promega) according to the manufacturer's instructions. The Firefly/Renilla luciferase ratio was calculated.
Kinase assay
293T cells were transiently transfected with either constitutively active CDK4 or p38 plasmid. Another set of 293T cells were transiently transfected with FLAG-MDMX plasmid or MDMX (S314A) mutant plasmid. After 48 h, MDMX and MDMX(S314A) were immunoprecipitated by FLAG-IP and then incubated with cell lysates expressing CDK4 or p38 in kinase assay buffer in the presence of 10 mM ATP. After 30 min incubation at 30°C, the reaction was terminated by addition of SDS loading dye and boiled. The products were analysed by western blot analysis using an anti-phosphoserine antibody.
Immunofluorescence
Cells were grown and transfected on round glass coverslips in 24-well plates, fixed with 4% PFA for 10 min, permeabilized with 0.1% Triton X-100 for 15 min, and then blocked with 1% BSA for 30 min. Cells were incubated with primary antibody overnight at 4°C, followed by incubation with fluorescent secondary antibody (Thermofisher Scientific) for 1 h in the dark, and mounted with mounting medium (Thermofisher Scientific). Images were taken with the EVOS FL imaging system (Thermofisher Scientific).
Quantitative real-time PCR
Total RNA from cells was extracted using TRIzol (Thermofisher Scientific), and quantified by a NanoDrop Spectrophotometry (Thermofisher Scientific). Complementary DNA (cDNA) was synthesized from 1 μg of total RNA using the High Capacity cDNA reverse transcription kit (BioRad). Quantitative PCR was carried out using PowerUp SYBR Green Master Mix (Thermofisher Scientific) according to the manufacturer's instructions. Primer sequences are reported in Supplementary Table S1 .
Cell viability and colony formation assays
Cell viability was tested using the AlamarBlue Assay (Invitrogen). Cells were seeded in 96-well plates at 2000 cells/well. After overnight incubation, cells were treated with different concentrations of drugs as indicated. The AlamarBlue assay was performed 4 days after treatment, according to the manufacturer's instructions, in four replicates. For colony formation assay, cells were seeded in six-well plates and cultured for 10 days. After fixation with 4% formaldehyde in phosphate buffer saline (PBS) for 10 min, colonies were stained with 0.5% crystal violet in 25% methanol. Stained colonies were then dissolved in 2% SDS and crystal violet absorbance was measured using a BioTek microplate reader.
SA-β-Gal assay
Cells were treated with Vemurafenib alone or combined with R428 or Foretinib at the indicated concentrations. After 9-10 days, cells were washed with PBS, fixed with 4% formaldehyde in PBS, rinsed and subjected to SA-β-Gal staining using the Senescence β-Galactosidase Staining Kit (Cell Signaling Technology, #9860) according to the manufacturer's instructions. Pictures were taken with the EVOS FL imaging system under light microscopy (Thermofisher Scientific).
Statistical analysis
Each experiment was repeated three times independently. All data were expressed as mean ± SEM. Statistical analysis was determined using one-way ANOVA or unpaired Student's t-test using GraphPad Prism, Version 6.0 g. A P-value <0.05 was considered statistically significant.
Supplementary material
Supplementary material is available at Journal of Molecular Cell Biology online.
